Form 4: STERIS CEO Daniel Carestio Reports Significant Share Sales Following Restricted Stock Vesting

STERIS plc's President and CEO, Daniel A. Carestio, reported the sale of over 17,600 ordinary shares in early June 2025, following the vesting of restricted stock and tax-related withholdings.

Summary

• Daniel A. Carestio, President and CEO, and a Director of STERIS plc, filed a Form 4 detailing recent transactions.
• On June 4, 2025, 4,283 restricted shares awarded on June 4, 2024, vested.
• Concurrently, 1,921 shares were withheld from the vested amount at a price of $242.1 per share to cover tax obligations.
• Following the tax withholding, Mr. Carestio's beneficial ownership stood at 69,011 ordinary shares.
• On June 5, 2025, Mr. Carestio sold a total of 17,626 ordinary shares across three separate transactions.
• The sales occurred at weighted average prices of $241.85 (7,520 shares), $242.67 (4,980 shares), and $243.49 (5,126 shares).
• These transactions were made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• After all reported transactions, Mr. Carestio's direct beneficial ownership of STERIS ordinary shares decreased to 51,385.
• As of June 4, 2025, 33,343 of the beneficially owned ordinary shares remain restricted, with various vesting schedules extending to October 2025, June 2026, June 2027, and June 2028.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there are significant sales by the CEO, they are part of a pre-arranged 10b5-1 plan and follow the vesting of restricted shares, which is a common and expected practice for executive compensation management. The continued holding of a substantial number of shares, including restricted ones, indicates ongoing alignment with shareholder interests.

Positives

• The vesting of 4,283 restricted shares on June 4, 2025, represents a realization of equity compensation for the CEO.
• The transactions were conducted under a Rule 10b5-1(c) plan, indicating pre-planned sales rather than reactive selling, which can be viewed positively for transparency and orderly market impact.

Negatives

• The President and CEO disposed of a significant number of shares (17,626 shares through sales and 1,921 shares for tax withholding), reducing his direct beneficial ownership from 69,011 to 51,385 shares.

Future Outlook

The document outlines future vesting schedules for 33,343 restricted ordinary shares held by Mr. Carestio, indicating continued long-term equity alignment, with restrictions lapsing between October 2025 and June 2028.

Industry Context

This Form 4 filing details routine insider transactions, common for executives managing their equity compensation and personal finances. It does not provide broader industry context or competitive analysis.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO, while pre-planned, slightly reduces his direct ownership stake. However, the existence of a 10b5-1 plan suggests an orderly disposition, minimizing potential market impact from unexpected insider selling. The CEO still retains a significant number of shares, including restricted ones, maintaining alignment with shareholder interests.
• Employees: No direct impact mentioned.

Next Steps

• Future vesting of 33,343 restricted ordinary shares held by Mr. Carestio on various dates between October 1, 2025, and June 5, 2028.

Key Dates

Keywords

STERIS plc, STE, Form 4, Insider Trading, Share Sales, Restricted Stock Units, Equity Compensation, CEO, Daniel A. Carestio, 10b5-1 Plan